Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 4/10

vs
industry
vs
history
Cash to Debt No Debt
NAS:ROSG's Cash to Debt is ranked higher than
93% of the 211 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.88 vs. NAS:ROSG: No Debt )
Ranked among companies with meaningful Cash to Debt only.
NAS:ROSG' s Cash to Debt Range Over the Past 10 Years
Min: 0.77  Med: 726.72 Max: No Debt
Current: No Debt
Equity to Asset 0.82
NAS:ROSG's Equity to Asset is ranked higher than
84% of the 186 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.58 vs. NAS:ROSG: 0.82 )
Ranked among companies with meaningful Equity to Asset only.
NAS:ROSG' s Equity to Asset Range Over the Past 10 Years
Min: -0.27  Med: 0.69 Max: 0.88
Current: 0.82
-0.27
0.88
Z-Score: -8.84
WACC vs ROIC
3.50%
-215.59%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 1/10

vs
industry
vs
history
Operating margin (%) -151.10
NAS:ROSG's Operating margin (%) is ranked lower than
76% of the 199 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.48 vs. NAS:ROSG: -151.10 )
Ranked among companies with meaningful Operating margin (%) only.
NAS:ROSG' s Operating margin (%) Range Over the Past 10 Years
Min: -9864.67  Med: -4112.94 Max: -151.1
Current: -151.1
-9864.67
-151.1
Net-margin (%) -166.01
NAS:ROSG's Net-margin (%) is ranked lower than
77% of the 199 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.51 vs. NAS:ROSG: -166.01 )
Ranked among companies with meaningful Net-margin (%) only.
NAS:ROSG' s Net-margin (%) Range Over the Past 10 Years
Min: -11003.33  Med: -5202.49 Max: -166.01
Current: -166.01
-11003.33
-166.01
ROE (%) -120.90
NAS:ROSG's ROE (%) is ranked lower than
86% of the 187 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -4.35 vs. NAS:ROSG: -120.90 )
Ranked among companies with meaningful ROE (%) only.
NAS:ROSG' s ROE (%) Range Over the Past 10 Years
Min: -545.27  Med: -84.49 Max: -47.3
Current: -120.9
-545.27
-47.3
ROA (%) -103.26
NAS:ROSG's ROA (%) is ranked lower than
86% of the 212 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -6.30 vs. NAS:ROSG: -103.26 )
Ranked among companies with meaningful ROA (%) only.
NAS:ROSG' s ROA (%) Range Over the Past 10 Years
Min: -240.7  Med: -78.2 Max: -40.87
Current: -103.26
-240.7
-40.87
ROC (Joel Greenblatt) (%) -245.03
NAS:ROSG's ROC (Joel Greenblatt) (%) is ranked lower than
68% of the 211 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -10.22 vs. NAS:ROSG: -245.03 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
NAS:ROSG' s ROC (Joel Greenblatt) (%) Range Over the Past 10 Years
Min: -1452.9  Med: -1046.33 Max: -202.49
Current: -245.03
-1452.9
-202.49
Revenue Growth (3Y)(%) 130.10
NAS:ROSG's Revenue Growth (3Y)(%) is ranked higher than
99% of the 141 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.80 vs. NAS:ROSG: 130.10 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
NAS:ROSG' s Revenue Growth (3Y)(%) Range Over the Past 10 Years
Min: 0  Med: 0 Max: 130.1
Current: 130.1
0
130.1
EBITDA Growth (3Y)(%) -15.20
NAS:ROSG's EBITDA Growth (3Y)(%) is ranked lower than
75% of the 123 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.80 vs. NAS:ROSG: -15.20 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
NAS:ROSG' s EBITDA Growth (3Y)(%) Range Over the Past 10 Years
Min: -69.6  Med: -29.7 Max: -4.6
Current: -15.2
-69.6
-4.6
EPS Growth (3Y)(%) -21.70
NAS:ROSG's EPS Growth (3Y)(%) is ranked lower than
74% of the 117 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -1.10 vs. NAS:ROSG: -21.70 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
NAS:ROSG' s EPS Growth (3Y)(%) Range Over the Past 10 Years
Min: -68.9  Med: -30.4 Max: 3.5
Current: -21.7
-68.9
3.5
» NAS:ROSG's 10-Y Financials

Financials (Next Earnings Date: Est. 2016-10-27)


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow
Oprt. Cash Flow & Net Income

» Details

Guru Trades

ROSG Guru Trades in

ROSG Guru Trades in

Q3 2014

ROSG Guru Trades in Q3 2014

Jim Simons 18,400 sh (New)
» More
Q4 2014

ROSG Guru Trades in Q4 2014

Jim Simons Sold Out
» More
» Details

Insider Trades

Latest Guru Trades with ROSG

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Medical Diagnostics & Research » Diagnostics & Research
Compare:OTCPK:VRTT, NAS:DRIO, NAS:HTGM, OTCPK:GNWSF, OTCPK:BZYR, NAS:GENE, NAS:WGBS, OTCPK:VILGF, NAS:NSPH, NAS:CAPN, NAS:BIOC, NAS:APPY, NAS:CHEK, OTCPK:MHTX, OTCPK:MDIT, NAS:ROKA, OTCPK:CBIS, OTCPK:PMSNF, NAS:CGIX, NAS:BASI » details
Traded in other countries:RQ1.Germany,
Rosetta Genomics Ltd is engaged in the development and commercialization of new diagnostic tests and therapeutics based on a group of genes known as microRNAs.

Rosetta Genomics, Ltd., develops diagnostic tests and therapeutic tools. Its product portfolio comprises of tests such as miRview mets2/mets, miRview squamous, miRview meso and miRview kidney.

Ratios

vs
industry
vs
history
P/B 1.22
ROSG's P/B is ranked higher than
88% of the 179 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.47 vs. ROSG: 1.22 )
Ranked among companies with meaningful P/B only.
ROSG' s P/B Range Over the Past 10 Years
Min: 0.48  Med: 2.36 Max: 37.02
Current: 1.22
0.48
37.02
P/S 1.44
ROSG's P/S is ranked higher than
80% of the 181 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.27 vs. ROSG: 1.44 )
Ranked among companies with meaningful P/S only.
ROSG' s P/S Range Over the Past 10 Years
Min: 1.33  Med: 30.08 Max: 200.29
Current: 1.44
1.33
200.29
Current Ratio 4.73
ROSG's Current Ratio is ranked higher than
79% of the 206 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.43 vs. ROSG: 4.73 )
Ranked among companies with meaningful Current Ratio only.
ROSG' s Current Ratio Range Over the Past 10 Years
Min: 1.14  Med: 6.91 Max: 26.26
Current: 4.73
1.14
26.26
Quick Ratio 4.73
ROSG's Quick Ratio is ranked higher than
83% of the 206 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.14 vs. ROSG: 4.73 )
Ranked among companies with meaningful Quick Ratio only.
ROSG' s Quick Ratio Range Over the Past 10 Years
Min: 1.14  Med: 6.91 Max: 26.26
Current: 4.73
1.14
26.26
Days Sales Outstanding 108.36
ROSG's Days Sales Outstanding is ranked lower than
79% of the 160 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 64.52 vs. ROSG: 108.36 )
Ranked among companies with meaningful Days Sales Outstanding only.
ROSG' s Days Sales Outstanding Range Over the Past 10 Years
Min: 38.98  Med: 159.8 Max: 885.73
Current: 108.36
38.98
885.73
Days Payable 62.81
ROSG's Days Payable is ranked higher than
52% of the 149 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 60.15 vs. ROSG: 62.81 )
Ranked among companies with meaningful Days Payable only.
ROSG' s Days Payable Range Over the Past 10 Years
Min: 62.27  Med: 657.9 Max: 1066.71
Current: 62.81
62.27
1066.71

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio -31.10
ROSG's 3-Year Average Share Buyback Ratio is ranked lower than
80% of the 129 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -5.80 vs. ROSG: -31.10 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
ROSG' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -236  Med: -68.2 Max: -6.3
Current: -31.1
-236
-6.3

Valuation & Return

vs
industry
vs
history
Price/Net Cash 2.29
ROSG's Price/Net Cash is ranked higher than
91% of the 64 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 10.94 vs. ROSG: 2.29 )
Ranked among companies with meaningful Price/Net Cash only.
ROSG' s Price/Net Cash Range Over the Past 10 Years
Min: 1.31  Med: 4.2 Max: 37.67
Current: 2.29
1.31
37.67
Price/Net Current Asset Value 1.52
ROSG's Price/Net Current Asset Value is ranked higher than
93% of the 117 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 8.50 vs. ROSG: 1.52 )
Ranked among companies with meaningful Price/Net Current Asset Value only.
ROSG' s Price/Net Current Asset Value Range Over the Past 10 Years
Min: 1.14  Med: 3.1 Max: 9.53
Current: 1.52
1.14
9.53
Price/Tangible Book 1.24
ROSG's Price/Tangible Book is ranked higher than
93% of the 154 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 5.65 vs. ROSG: 1.24 )
Ranked among companies with meaningful Price/Tangible Book only.
ROSG' s Price/Tangible Book Range Over the Past 10 Years
Min: 0.88  Med: 2.6 Max: 26.84
Current: 1.24
0.88
26.84
Price/Median PS Value 0.05
ROSG's Price/Median PS Value is ranked higher than
96% of the 164 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.05 vs. ROSG: 0.05 )
Ranked among companies with meaningful Price/Median PS Value only.
ROSG' s Price/Median PS Value Range Over the Past 10 Years
Min: 0.04  Med: 1.1 Max: 6.25
Current: 0.05
0.04
6.25
Earnings Yield (Greenblatt) (%) -223.94
ROSG's Earnings Yield (Greenblatt) (%) is ranked lower than
97% of the 205 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -1.00 vs. ROSG: -223.94 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
ROSG' s Earnings Yield (Greenblatt) (%) Range Over the Past 10 Years
Min: -298.91  Med: 182.9 Max: 691
Current: -223.94
-298.91
691

More Statistics

Revenue (TTM) (Mil) $10.55
EPS (TTM) $ -1.05
Beta0.23
Short Percentage of Float4.00%
52-Week Range $0.71 - 2.89
Shares Outstanding (Mil)20.85

Analyst Estimate

Dec16 Dec17 Dec18 Dec19
Revenue (Mil $) 26 35
EPS ($) -0.73 -0.55 -0.37 -0.17
EPS w/o NRI ($) -0.73 -0.55 -0.37 -0.17
EPS Growth Rate
(3Y to 5Y Estimate)
N/A
Dividends Per Share ($)
» More Articles for NAS:ROSG

Headlines

Articles On GuruFocus.com
Rosetta Genomics Reports Third Quarter 2008 Financial Results; Records First Revenues of $705,000; $ Dec 08 2008 

More From Other Websites
Edited Transcript of ROSG earnings conference call or presentation 26-Sep-16 8:30pm GMT Sep 27 2016
Rosetta Genomics Reports 2016 Second Quarter Financial Results Sep 26 2016
Rosetta Genomics Reports 2016 Second Quarter Financial Results Sep 26 2016
Q2 2016 Rosetta Genomics Ltd Earnings Release - After Market Close Sep 26 2016
Rosetta Genomics to Host 2016 Second Quarter Financial Results and Business Update Conference Call... Sep 20 2016
Rosetta Genomics to Host 2016 Second Quarter Financial Results and Business Update Conference Call... Sep 20 2016
Rosetta Genomics to Present at Upcoming September Conferences Sep 19 2016
Data Validating the Utility of RosettaGX Reveal™ with Liquid-based Cytology Samples will be... Sep 14 2016
RosettaGX Reveal™ Thyroid miRNA Classifier Now available to be Utilized on ThinPrep® Samples Sep 07 2016
RosettaGX Reveal™ Thyroid miRNA Classifier Now Available to Be Utilized on ThinPrep® Samples Sep 07 2016
Rosetta Genomics Selected by a Global Pharmaceutical Company to Supply FISH Testing Services for... Aug 24 2016
Rosetta Genomics Selected by a Global Pharmaceutical Company to Supply FISH Testing Services for... Aug 24 2016
Rosetta Genomics Expands Molecular Diagnostics Test Menu with Launch of OncoGxSelect™ from Admera... Aug 04 2016
Rosetta Genomics Expands Molecular Diagnostics Test Menu with Launch of OncoGxSelect™ from Admera... Aug 04 2016
Rosetta Expands Managed Care Coverage with New Preferred Provider Agreement with Galaxy Health... Aug 02 2016
Rosetta Genomics Receives U.S. Patent Allowance for microRNA-based Ovarian Cancer Treatment Jul 11 2016
Rosetta Genomics Gets Patent Allowance For microRNA-based Ovarian Cancer Treatment Jul 11 2016
Rosetta Genomics Receives U.S. Patent Allowance for microRNA-based Ovarian Cancer Treatment Jul 11 2016
Rosetta Genomics to Present at Cantor Fitzgerald’s 2nd Annual Healthcare Conference Jul 06 2016
Rosetta Genomics to Present at Cantor Fitzgerald’s 2nd Annual Healthcare Conference Jul 06 2016

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)